JERUSALEM, May 15 (Reuters) - BiomX, which is developing drugs using microbiome bacteria, said on Monday it raised $24 million in an early stage funding round led by OrbiMed, Jonhnson & Johnson Innovation and Takeda Ventures.
Seventure Partners, MiraeAsset, SBI Japan-Israel Innovation Fund and other European investors also participated, the Israel-based company said.
The funds will be used to advance the firm’s therapeutic pipeline towards clinical stages.
BiomX develops treatments to alleviate diseases stemming from an imbalance in the microbiome - the bacteria in the human body. Its pipeline consists of products for the treatment of acne, inflammatory bowel disease and cancer. (Reporting by Steven Scheer)